Mounjaro (also known by its generic name, tirzepatide) is a once-weekly injectable medication that is FDA-approved for treating type 2 diabetes, reiterates Katherine Saunders, MD, an obesity medicine physician, clinical assistant professor of medicine at Weill Cornell Medicine, and co-founder of Intellihealth
After 68 weeks, participants receiving 2.4 mg had an average HbA1c of 6.4%, in the prediabetic range, and therefore below the threshold to diagnose T2DM, compared to 7.8% in the placebo group
In contrast, when a healthcare provider diagnoses B12 deficiencyvia blood tests and clinical evaluationB12 injections serve a medical purpose: correcting a documented biochemical imbalance and preventing the progression of serious conditions
This mechanism relies on intact pituitary and hypothalamic function, making efficacy dependent on baseline hormonal reserve and individual receptor sensitivity
In clinical trials, many participants experienced substantial losses roughly 15% of initial body weight on average over a 68-week course of treatment
